Myostatin - From the mighty mouse to cardiovascular disease and cachexia

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 216-224

  Dschietzig, Thomas Bernd ^a,b  

^a IMMUNDIAGNOSTIK AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Heart failure; Insulin resistance; Metabolism; Myostatin

Indexed keywords

MYOSTATIN;

ANIMAL; CACHEXIA; CARDIOVASCULAR DISEASE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; MOUSE; OBESITY; SECRETION (PROCESS);

ANIMALS; CACHEXIA; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; MICE; MYOSTATIN; OBESITY;

EID: 84898621236     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.021     Document Type: Review

References (123)

1. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387:83-90.
2. Grobet L., Martin L.J., Poncelet D., et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997, 17:71-74.
3. Kambadur R., Sharma M., Smith T.P., Bass J.J. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997, 7:910-916.
4. Marchitelli C., Savarese M.C., Crisa A., Nardone A., Marsan P.A., Valentini A. Double muscling in Marchigiana beef breed is caused by a stop codon in the third exon of myostatin gene. Mamm Genome 2003, 14:392-395.
5. McPherron A.C., Lee S.J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A 1997, 94:12457-12461.
6. Bogdanovich S., Krag T.O., Barton E.R., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418-421.
7. Wagner K.R., McPherron A.C., Winik N., Lee S.J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002, 52:832-836.
8. Wells D.J. Gene doping: the hype and the reality. Br J Pharmacol 2008, 154:623-631.
9. George I., Bish L.T., Kamalakkannan G., et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail 2010, 12:444-453.
10. Gruson D., Ahn S.A., Ketelslegers J.M., Rousseau M.F. Increased plasma myostatin in heart failure. Eur J Heart Fail 2011, 13:734-736.
11. Hittel D.S., Axelson M., Sarna N., Shearer J., Huffman K.M., Kraus W.E. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 2010, 42:2023-2029.
12. Heineke J., Auger-Messier M., Xu J., et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010, 121:419-425.
13. Lenk K., Schur R., Linke A., et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 2009, 11:342-348.
14. Argiles J.M., Orpi M., Busquets S., Lopez-Soriano F.J. Myostatin: more than just a regulator of muscle mass. Drug Discov Today 2012, 17:702-709.
15. Lee S.J. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004, 20:61-86.
16. Rodgers B.D., Garikipati D.K. Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocr Rev 2008, 29:513-534.
17. Gonzalez-Cadavid N.F., Taylor W.E., Yarasheski K., et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A 1998, 95:14938-14943.
18. Sazanov A., Ewald D., Buitkamp J., Fries R. A molecular marker for the chicken myostatin gene (GDF8) maps to 7p11. Anim Genet 1999, 30:388-389.
19. Smith T.P., Lopez-Corrales N.L., Kappes S.M., Sonstegard T.S. Myostatin maps to the interval containing the bovine mh locus. Mamm Genome 1997, 8:742-744.
20. Sonstegard T.S., Rohrer G.A., Smith T.P. Myostatin maps to porcine chromosome 15 by linkage and physical analyses. Anim Genet 1998, 29:19-22.
21. Stratil A., Kopecny M. Genomic organization, sequence and polymorphism of the porcine myostatin (GDF8; MSTN) gene. Anim Genet 1999, 30:468-470.
22. Szabo G., Dallmann G., Muller G., Patthy L., Soller M., Varga L. A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice. Mamm Genome 1998, 9:671-672.
23. Varga L., Muller G., Szabo G., et al. Mapping modifiers affecting muscularity of the myostatin mutant (Mstn(Cmpt-dl1Abc)) compact mouse. Genetics 2003, 165:257-267.
24. Walling G.A., Visscher P.M., Wilson A.D., McTeir B.L., Simm G., Bishop S.C. Mapping of quantitative trait loci for growth and carcass traits in commercial sheep populations. J Anim Sci 2004, 82:2234-2245.
25. Kerr T., Roalson E.H., Rodgers B.D. Phylogenetic analysis of the myostatin gene sub-family and the differential expression of a novel member in zebrafish. Evol Dev 2005, 7:390-400.
26. Xu C., Wu G., Zohar Y., Du S.J. Analysis of myostatin gene structure, expression and function in zebrafish. J Exp Biol 2003, 206:4067-4079.
27. Rodgers B.D., Weber G.M. Sequence conservation among fish myostatin orthologues and the characterization of two additional cDNA clones from Morone saxatilis and Morone americana. Comp Biochem Physiol B Biochem Mol Biol 2001, 129:597-603.
28. Hill J.J., Davies M.V., Pearson A.A., et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002, 277:40735-40741.
29. Lee S.J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001, 98:9306-9311.
30. Thies R.S., Chen T., Davies M.V., et al. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001, 18:251-259.
31. Hill J.J., Qiu Y., Hewick R.M., Wolfman N.M. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 2003, 17:1144-1154.
32. Kondas K., Szlama G., Trexler M., Patthy L. Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11. J Biol Chem 2008, 283:23677-23684.
33. Miura T., Kishioka Y., Wakamatsu J., et al. Decorin binds myostatin and modulates its activity to muscle cells. Biochem Biophys Res Commun 2006, 340:675-680.
34. Nicholas G., Thomas M., Langley B., et al. Titin-cap associates with, and regulates secretion of, Myostatin. J Cell Physiol 2002, 193:120-131.
35. Anderson S.B., Goldberg A.L., Whitman M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 2008, 283:7027-7035.
36. Wang H., Zhang Q., Zhu D. hSGT interacts with the N-terminal region of myostatin. Biochem Biophys Res Commun 2003, 311:877-883.
37. Bogdanovich S., Perkins K.J., Krag T.O., Whittemore L.A., Khurana T.S. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 2005, 19:543-549.
38. Wolfman N.M., McPherron A.C., Pappano W.N., et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A 2003, 100:15842-15846.
39. Haidet A.M., Rizo L., Handy C., et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A 2008, 105:4318-4322.
40. Lee S.J. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2007, 2:e789.
41. Lee S.J. Extracellular regulation of myostatin: a molecular rheostat for muscle mass. Immunol Endocr Metab Agents Med Chem 2010, 10:183-194.
42. Lee S.J. Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One 2008, 3:e1628.
43. Allen D.L., Greybeck B.J., Hanson A.M., Cleary A.S., Lindsay S.F. Skeletal muscle expression of bone morphogenetic protein-1 and tolloid-like-1 extracellular proteases in different fiber types and in response to unloading, food deprivation and differentiation. J Physiol Sci 2010, 60:343-352.
44. McFarlane C., Langley B., Thomas M., et al. Proteolytic processing of myostatin is auto-regulated during myogenesis. Dev Biol 2005, 283:58-69.
45. Lee S.J., Lee Y.S., Zimmers T.A., et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol 2010, 24:1998-2008.
46. Matsakas A., Bozzo C., Cacciani N., et al. Effect of swimming on myostatin expression in white and red gastrocnemius muscle and in cardiac muscle of rats. Exp Physiol 2006, 91:983-994.
47. Sharma M., Kambadur R., Matthews K.G., et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999, 180:1-9.
48. Kim J.S., Cross J.M., Bamman M.M. Impact of resistance loading on myostatin expression and cell cycle regulation in young and older men and women. Am J Physiol Endocrinol Metab 2005, 288:E1110-E1119.
49. Hulmi J.J., Tannerstedt J., Selanne H., Kainulainen H., Kovanen V., Mero A.A. Resistance exercise with whey protein ingestion affects mTOR signaling pathway and myostatin in men. J Appl Physiol (1985) 2009, 106:1720-1729.
50. Louis E., Raue U., Yang Y., Jemiolo B., Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol (1985) 2007, 103:1744-1751.
51. Allen D.L., Unterman T.G. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007, 292:C188-C199.
52. Ma K., Mallidis C., Artaza J., Taylor W., Gonzalez-Cadavid N., Bhasin S. Characterization of 5'-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab 2001, 281:E1128-E1136.
53. Artaza J.N., Bhasin S., Mallidis C., Taylor W., Ma K., Gonzalez-Cadavid N.F. Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J Cell Physiol 2002, 190:170-179.
54. Ma K., Mallidis C., Bhasin S., et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003, 285:E363-E371.
55. Allen D.L., Loh A.S. Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. Am J Physiol Cell Physiol 2011, 300:C124-C137.
56. Shyu K.G., Ko W.H., Yang W.S., Wang B.W., Kuan P. Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res 2005, 68:405-414.
57. Wang B.W., Chang H., Kuan P., Shyu K.G. Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway. J Endocrinol 2008, 197:85-93.
58. Gruson D., Ginion A., Lause P., Ketelslegers J.M., Thissen J.P., Bertrand L. Urotensin II and urocortin trigger the expression of myostatin, a negative regulator of cardiac growth, in cardiomyocytes. Peptides 2012, 33:351-353.
59. Bish L.T., Morine K.J., Sleeper M.M., Sweeney H.L. Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS One 2010, 5:e10230.
60. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647.
61. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-791.
62. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003, 23:7230-7242.
63. Kemaladewi D.U., de Gorter D.J., Aartsma-Rus A., et al. Cell-type specific regulation of myostatin signaling. FASEB J 2012, 26:1462-1472.
64. Lee S.J., Reed L.A., Davies M.V., et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 2005, 102:18117-18122.
65. Souza T.A., Chen X., Guo Y., et al. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 2008, 22:2689-2702.
66. Kim H.S., Liang L., Dean R.G., Hausman D.B., Hartzell D.L., Baile C.A. Inhibition of preadipocyte differentiation by myostatin treatment in 3T3-L1 cultures. Biochem Biophys Res Commun 2001, 281:902-906.
67. McPherron A.C. Metabolic functions of myostatin and Gdf11. Immunol Endocr Metab Agents Med Chem 2010, 10:217-231.
68. Hittel D.S., Berggren J.R., Shearer J., Boyle K., Houmard J.A. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009, 58:30-38.
69. Allen D.L., Cleary A.S., Speaker K.J., et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008, 294:E918-E927.
70. Feldman B.J., Streeper R.S., Farese R.V., Yamamoto K.R. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci U S A 2006, 103:15675-15680.
71. Guo T., Jou W., Chanturiya T., Portas J., Gavrilova O., McPherron A.C. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One 2009, 4:e4937.
72. Stolz L.E., Li D., Qadri A., Jalenak M., Klaman L.D., Tobin J.F. Administration of myostatin does not alter fat mass in adult mice. Diabetes Obes Metab 2008, 10:135-142.
73. Bernardo B.L., Wachtmann T.S., Cosgrove P.G., et al. Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice. PLoS One 2010, 5:e11307.
74. Guo T., Bond N.D., Jou W., Gavrilova O., Portas J., McPherron A.C. Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 2012, 61:2414-2423.
75. Ji M., Zhang Q., Ye J., Wang X., Yang W., Zhu D. Myostatin induces p300 degradation to silence cyclin D1 expression through the PI3K/PTEN/Akt pathway. Cell Signal 2008, 20:1452-1458.
76. Morissette M.R., Cook S.A., Foo S., et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res 2006, 99:15-24.
77. Morissette M.R., Cook S.A., Buranasombati C., Rosenberg M.A., Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009, 297:C1124-C1132.
78. Palsgaard J., Brons C., Friedrichsen M., et al. Gene expression in skeletal muscle biopsies from people with type 2 diabetes and relatives: differential regulation of insulin signaling pathways. PLoS One 2009, 4:e6575.
79. Antony N., Bass J.J., McMahon C.D., Mitchell M.D. Myostatin regulates glucose uptake in BeWo cells. Am J Physiol Endocrinol Metab 2007, 293:E1296-E1302.
80. Chen Y., Ye J., Cao L., Zhang Y., Xia W., Zhu D. Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells. Int J Biochem Cell Biol 2010, 42:2072-2081.
81. Wilkes J.J., Lloyd D.J., Gekakis N. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 2009, 58:1133-1143.
82. Akpan I., Goncalves M.D., Dhir R., et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 2009, 33:1265-1273.
83. Tu P., Bhasin S., Hruz P.W., et al. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes 2009, 58:1739-1748.
84. Ehehalt S., Schweizer R., Blumenstock G., et al. Investigation of myostatin serum levels before and after a 6-month lifestyle intervention program in obese children. Exp Clin Endocrinol Diabetes 2011, 119:238-242.
85. Brandt C., Nielsen A.R., Fischer C.P., Hansen J., Pedersen B.K., Plomgaard P. Plasma and muscle myostatin in relation to type 2 diabetes. PLoS One 2012, 7:e37236.
86. Morissette M.R., Stricker J.C., Rosenberg M.A., et al. Effects of myostatin deletion in aging mice. Aging Cell 2009, 8:573-583.
87. Artaza J.N., Reisz-Porszasz S., Dow J.S., et al. Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J Endocrinol 2007, 194:63-76.
88. Artaza J.N., Singh R., Ferrini M.G., Braga M., Tsao J., Gonzalez-Cadavid N.F. Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts. J Endocrinol 2008, 196:235-249.
89. Shyu K.G., Lu M.J., Wang B.W., Sun H.Y., Chang H. Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest 2006, 36:713-719.
90. Zamora E., Simo R., Lupon J., et al. Serum myostatin levels in chronic heart failure. Rev Esp Cardiol 2010, 63:992-996.
91. Wintgens K.F., Dschietzig T., Stoeva S., Paulsson M., Armbruster F.P. Plasma myostatin measured by a competitive ELISA using a highly specific antiserum. Clin Chim Acta 2012, 413:1288-1294.
92. Argiles J.M., Anker S.D., Evans W.J., et al. Consensus on cachexia definitions. J Am Med Dir Assoc 2010, 11:229-230.
93. Anker S.D., Negassa A., Coats A.J., et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003, 361:1077-1083.
94. Springer J., Adams V., Anker S.D. Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia. Circulation 2010, 121:354-356.
95. Lenk K., Schuler G., Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachex Sarcopenia Muscle 2010, 1:9-21.
96. Elkina Y., von H.S., Anker S.D., Springer J. The role of myostatin in muscle wasting: an overview. J Cachex Sarcopenia Muscle 2011, 2:143-151.
97. Lenk K., Palus S., Schur R., et al. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachex Sarcopenia Muscle 2013, 4:63-69.
98. Anker M.S., von Haehling S., Springer J., Banach M., Anker S.D. Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Arch Med Sci 2013, 9:166-171.
99. Zimmers T.A., Davies M.V., Koniaris L.G., et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486-1488.
100. Jeanplong F., Bass J.J., Smith H.K., et al. Prolonged underfeeding of sheep increases myostatin and myogenic regulatory factor Myf-5 in skeletal muscle while IGF-I and myogenin are repressed. J Endocrinol 2003, 176:425-437.
101. Langley B., Thomas M., Bishop A., Sharma M., Gilmour S., Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002, 277:49831-49840.
102. Megeney L.A., Kablar B., Garrett K., Anderson J.E., Rudnicki M.A. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 1996, 10:1173-1183.
103. Steelman C.A., Recknor J.C., Nettleton D., Reecy J.M. Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB J 2006, 20:580-582.
104. Yang W., Chen Y., Zhang Y., Wang X., Yang N., Zhu D. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Cancer Res 2006, 66:1320-1326.
105. McFarlane C., Plummer E., Thomas M., et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006, 209:501-514.
106. Yang W., Zhang Y., Li Y., Wu Z., Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 2007, 282:3799-3808.
107. Lipina C., Kendall H., McPherron A.C., Taylor P.M., Hundal H.S. Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice. FEBS Lett 2010, 584:2403-2408.
108. Breitbart A., Auger-Messier M., Molkentin J.D., Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol 2011, 300:H1973-H1982.
109. Loncar G., Fulster S., von H.S., Popovic V. Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol 2013, 162:77-85.
110. Lenk K., Erbs S., Hollriege R., et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2011, 19:404-411.
111. Lokireddy S., Wijesoma I.W., Bonala S., et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J 2012, 446:23-36.
112. Benny Klimek M.E., Aydogdu T., Link M.J., Pons M., Koniaris L.G., Zimmers T.A. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010, 391:1548-1554.
113. Busquets S., Toledo M., Orpi M., et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachex Sarcopenia Muscle 2012, 3:37-43.
114. Zhou X., Wang J.L., Lu J., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
115. Busquets S., Toledo M., Marmonti E., et al. Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncol Lett 2012, 3:185-189.
116. Aversa Z., Bonetto A., Penna F., et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 2012, 19:1350-1356.
117. Gilson H., Schakman O., Combaret L., et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007, 148:452-460.
118. Hayot M., Rodriguez J., Vernus B., et al. Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol Cell Endocrinol 2011, 332:38-47.
119. Plant P.J., Brooks D., Faughnan M., et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2010, 42:461-471.
120. Man W.D., Natanek S.A., Riddoch-Contreras J., et al. Quadriceps myostatin expression in COPD. Eur Respir J 2010, 36:686-688.
121. Testelmans D., Crul T., Maes K., et al. Atrophy and hypertrophy signalling in the diaphragm of patients with COPD. Eur Respir J 2010, 35:549-556.
122. Oshima Y., Ouchi N., Shimano M., et al. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 2009, 120:1606-1615.
123. Panse K.D., Felkin L.E., Lopez-Olaneta M.M., et al. Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes. J Cardiovasc Transl Res 2012, 5:814-826.